Just lately, we have proven that SCN-DOX shows favourable pharmaceutical homes in a colorectal most cancers xenograft model, with an enhanced biodistribution, increased treatment method efficacy and diminished toxicity compared
Supplied our SCN-DOX is capable to produce much more therapeutic agents to the xenograft tumor (Figure five), we proceeded to establish the antitumor exercise of SCN-DOX in vivo. Mice bearing…